Roche's Avastin gets US approval for kidney cancer
This article was originally published in Scrip
Executive Summary
The US FDA has approved Roche's Avastin (bevacizumab) plus interferon alpha for metastatic renal cell carcinoma (RCC). The drug is now approved for five different types of cancer in the US.